Sun Pharma Advanced Research Company Ltd. announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PDP-716 for the treatment of patients with Glaucoma, due to inspection findings at a third-party Active Pharmaceutical Ingredient (API) manufacturing facility. The FDA did not raise any issues with the PDP-176 clinical efficacy or safety and no additional clinical data or trials have been requested. SPARC is committed to work closely with Visiox, the FDA and the third-party manufacturer to resubmit the NDA as quickly as possible.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
219.4 INR | +2.26% | +2.40% | -23.50% |
1st Jan change | Capi. | |
---|---|---|
-23.50% | 834M | |
+30.15% | 682B | |
+30.35% | 586B | |
-3.75% | 364B | |
+17.66% | 327B | |
+3.60% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+7.45% | 165B |
- Stock Market
- Equities
- SPARC Stock
- News Sun Pharma Advanced Research Company Limited
- Sun Pharma Advanced Research Company Limited Announces That FDA Issues Complete Response Letter for Pdp-716 Nda Due to Inspection Findings At Third-Party Api Manufacturing Facility